Standard BioTools Inc.

LAB Healthcare Medical Devices

In the quarter to June 2026, revenue fell 7.62%, EPS grew 22.2%, free cash flow grew 52.8% and total debt was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.

0.63 0.03 −4.55%
Market cap
$258.5M
P/E
2.9×
Fwd P/E
−11.5×
Dividend yield
—
F-score
4/9
Altman Z
−0.82
Beneish M
−2.93
Dividend safety
n/a

Standard BioTools Inc. (LAB) P/E ratio

Alert me on P/E ratio

As of 16 October 2026, Standard BioTools Inc. (LAB) trades at a P/E ratio of 2.9×. Over the past ten years it has ranged from 0.0× (March 2026) to 6.4× (June 2026); the current reading is higher than 95% of that period. That is below the Medical Devices industry median of 23.2× and below the Healthcare sector median of 23.0×.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —
FY2021 0.0× —
FY2020 0.0× —
FY2019 0.0× —
FY2018 0.0× —
FY2017 0.0× —
FY2016 0.0× —

Quarterly newest first

Period P/E ratio Change
Jun 2026 3.7× (18.97%)
Mar 2026 4.6× —
Dec 2025 0.0× —
Sep 2025 0.0× —
42 more quarters

Against its own ten years

Low 0.0× High 6.4×
Ten-year median 0.0×
Current reading's percentile 95

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on LAB